Recent News

• 11.04.2026 - OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
• 11.04.2026 - OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
• 10.28.2026 - OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
• 10.28.2026 - OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
• 10.27.2026 - OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
• 10.27.2026 - OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
• 10.15.2026 - Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
• 09.08.2026 - OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
• 09.08.2026 - OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
• 08.13.2026 - OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

Recent Filings

• 11.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2026 - 8-K Current report
• 11.04.2026 - EX-99.1 EX-99.1
• 10.15.2026 - 8-K Current report
• 10.02.2026 - 8-K Current report
• 08.28.2026 - 10-Q/A Quarterly report [Sections 13 or 15(d)]
• 08.28.2026 - 10-Q/A Quarterly report [Sections 13 or 15(d)]
• 08.14.2026 - 8-K Current report
• 08.07.2026 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 07.28.2026 - 4 Statement of changes in beneficial ownership of securities